title: The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
abstract: BACKGROUND
  Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis.
  
  
  OBJECTIVE
  To separate the effects of RSV LRTI and an atopic diathesis on subsequent recurrent wheezing, we examined the protective effect of previous palivizumab administration against subsequent recurrent wheeze in infants with and without a family history of atopy.
  
  
  METHODS
  A prospective multicenter, matched, double cohort study was conducted in 27 centers in Europe and Canada. The rates of physician-diagnosed recurrent wheezing in premature infants <36 weeks gestation who had received palivizumab in the first year of life were compared to those of gestational age-matched controls.
  
  
  RESULTS
  The relative protective effect of palivizumab on physician-diagnosed recurrent wheezing through the ages of 2 to 5 years was 68% in those with no family history of asthma (odds ratio, 0.32; (95% CI, 0.14-0.75; N = 146 palivizumab-treated, 171 untreated) and 80% in those with no family history of atopy or food allergies (odds ratio, 0.20; 95% CI, 0.07-0.59; N = 101 palivizumab-treated, 100 untreated). In contrast, there was no effect of palivizumab on subsequent recurrent wheezing in the 90 children with a family history of atopy or food allergies compared to 130 untreated infants with atopic families.
  
  
  CONCLUSIONS
  Respiratory syncytial virus prophylaxis in nonatopic children decreases by 80% the relative risk of recurrent wheezing but does not have any effect in infants with an atopic family history. This suggests that RSV predisposes to recurrent wheezing in an atopy-independent mechanism.
authors.affiliation: Department of Pediatric Infectious Diseases, University of Colorado School of Medicine, and The Children's Hospital, Aurora, Colo, USA. eric.simoes@ucdenver.edu
authors.forename: Eric A F
authors.initials: EA
authors.lastname: Simões
authors.forename: Xavier
authors.initials: X
authors.lastname: Carbonell-Estrany
authors.forename: Christian H L
authors.initials: CH
authors.lastname: Rieger
authors.forename: Ian
authors.initials: I
authors.lastname: Mitchell
authors.forename: Linda
authors.initials: L
authors.lastname: Fredrick
authors.forename: Jessie R
authors.initials: JR
authors.lastname: Groothuis
mesh_terms: D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000209:etiology / Q000517:prevention & control; D002675:Child, Preschool; D004198:Disease Susceptibility; D005260:Female; D005500:Follow-Up Studies; D005512:Food Hypersensitivity / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D000069455:Palivizumab; D011446:Prospective Studies; D012135:Respiratory Sounds / Q000187:drug effects; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000188:drug therapy; D012136:Respiratory Syncytial Viruses; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab